- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-functional neuroendocrine tumours of midgut or suspected midgut origin
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Octreotide – July 2019
Octreotide: Injection (modified release) 30 mg (as acetate), vial and diluent syringe; Sandostatin®
Last updated
1 November 2019